About DiscGenics
DiscGenics is a company based in Salt Lake City (United States) founded in 2008.. DiscGenics has raised $65.84 million across 3 funding rounds from investors including CareNet, Mitsubishi UFJ Capital and Medical Incubator Japan. The company has 45 employees as of December 31, 2022. DiscGenics operates in a competitive market with competitors including ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others.
- Headquarter Salt Lake City, United States
- Employees 45 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Discgenics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$65.84 M (USD)
in 3 rounds
-
Latest Funding Round
$50 M (USD), Series C
Aug 25, 2020
-
Investors
CareNet
& 2 more
-
Employee Count
45
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
5 people
Software Development Team
3 people
Human Resources and Administration
1 people
Unlock access to complete
Funding Insights of DiscGenics
DiscGenics has successfully raised a total of $65.84M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $50.0M
-
First Round
First Round
(20 Oct 2011)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Series C - DiscGenics | Valuation |
investors |
|
| Sep, 2017 | Amount | Series B - DiscGenics | Valuation |
investors |
|
| Oct, 2011 | Amount | Seed - DiscGenics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in DiscGenics
DiscGenics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include CareNet, Mitsubishi UFJ Capital and Medical Incubator Japan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is invested in AI, energy, and various sectors.
|
Founded Year | Domain | Location | |
|
Investment in innovative healthcare startups is facilitated by this company.
|
Founded Year | Domain | Location | |
|
Medical sales support and education services for pharmaceuticals are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by DiscGenics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - DiscGenics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Discgenics Comparisons
Competitors of DiscGenics
DiscGenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ViaCyte, Capricor Therapeutics, Neurona Therapeutics, EpiBone and Gamida Cell, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
|
| domain | founded_year | HQ Location |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
|
| domain | founded_year | HQ Location |
Cell-based therapies are developed for intractable neurological diseases.
|
|
| domain | founded_year | HQ Location |
Developer of stem cells to regrow damaged bones
|
|
| domain | founded_year | HQ Location |
Cell therapies for cancer and serious diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Discgenics
Frequently Asked Questions about DiscGenics
When was DiscGenics founded?
DiscGenics was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Where is DiscGenics located?
DiscGenics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Is DiscGenics a funded company?
DiscGenics is a funded company, having raised a total of $65.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.84M, raised on Oct 20, 2011.
How many employees does DiscGenics have?
As of Dec 31, 2022, the latest employee count at DiscGenics is 45.
What does DiscGenics do?
DiscGenics was established in 2008 in Salt Lake City, United States, within the spinal therapeutics sector. A tissue engineering approach is employed, leveraging proprietary adult human disc stem cells to address degenerative disc disease. Two products are under development: Injectable Discogenic Cell Therapy (IDCT), an off-the-shelf allogeneic treatment for moderately degenerated discs delivered via non-surgical percutaneous injection, and Surgical Discogenic Cell Therapy (SDCT), a minimally invasive implant for herniated discs.
Who are the top competitors of DiscGenics?
DiscGenics's top competitors include EpiBone, Neurona Therapeutics and Gamida Cell.
Who are DiscGenics's investors?
DiscGenics has 3 investors. Key investors include CareNet, Mitsubishi UFJ Capital, and Medical Incubator Japan.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.